Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
Phase IIA Trial of Acolbifene (20 mg) vs Low Dose Tamoxifen (5 mg) in Pre-menopausal Women at High Risk for Development of Breast Cancer
Sponsor: National Cancer Institute (NCI)
Listed as NCT05941520, this PHASE2 trial focuses on Breast Atypical Hyperplasia and Breast Carcinoma and remains actively recruiting participants. Sponsored by National Cancer Institute (NCI), it has been updated 16 times since 2024, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
16 versions recorded-
Mar 2026 — Present [monthly]
Recruiting PHASE2
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE2
-
Jan 2026 — Feb 2026 [monthly]
Recruiting PHASE2
-
Nov 2025 — Jan 2026 [monthly]
Recruiting PHASE2
-
Jun 2025 — Nov 2025 [monthly]
Recruiting PHASE2
▶ Show 11 earlier versions
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE2
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE2
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE2
-
Oct 2024 — Mar 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
-
May 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
-
Nov 2023 — May 2024 [monthly]
Not Yet Recruiting PHASE2
-
Oct 2023 — Nov 2023 [monthly]
Not Yet Recruiting PHASE2
-
Sep 2023 — Oct 2023 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2023 — Sep 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .